Free tool
FAERS Monitor: Remeron
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020415 or its brand name (Remeron, Mirtazapine). Reports on generic versions are filed under their own applications.
Reports
93,069
Serious
77,961
84% of reports
Hospitalization
38,021
Death reported
14,287
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea5,124
- fatigue5,006
- drug ineffective4,903
- fall4,248
- diarrhoea4,175
- off label use4,082
- toxicity to various agents3,985
- dizziness3,670
- anxiety3,652
- dyspnoea3,602
- death3,521
- drug interaction3,468
- vomiting3,362
- depression3,346
- headache3,238
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,058 |
| 2005 | 1,207 |
| 2006 | 1,307 |
| 2007 | 1,300 |
| 2008 | 1,305 |
| 2009 | 1,892 |
| 2010 | 2,234 |
| 2011 | 2,590 |
| 2012 | 2,748 |
| 2013 | 2,527 |
| 2014 | 3,087 |
| 2015 | 4,008 |
| 2016 | 4,596 |
| 2017 | 5,114 |
| 2018 | 6,608 |
| 2019 | 7,303 |
| 2020 | 7,212 |
| 2021 | 6,131 |
| 2022 | 6,330 |
| 2023 | 6,409 |
| 2024 | 6,273 |
| 2025 | 6,720 |
| 2026 | 5,107 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,961,090 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| toxicity to various agentsSignal | 3,985 | 5.4 | 5.3 | 14,229 |
| drug interactionSignal | 3,468 | 5.0 | 4.9 | 11,026 |
| depressionSignal | 3,346 | 3.4 | 3.2 | 5,516 |
| anxietySignal | 3,652 | 2.9 | 2.8 | 4,627 |
| fallSignal | 4,248 | 2.9 | 2.8 | 5,336 |
| dizziness | 3,670 | 1.7 | 1.6 | 997 |
| vomiting | 3,362 | 1.6 | 1.6 | 810 |
| nausea | 5,124 | 1.5 | 1.4 | 783 |
| diarrhoea | 4,175 | 1.5 | 1.4 | 630 |
| fatigue | 5,006 | 1.5 | 1.4 | 737 |
| dyspnoea | 3,602 | 1.4 | 1.4 | 496 |
| headache | 3,238 | 1.2 | 1.1 | 80 |
| off label use | 4,082 | 1.1 | 1.0 | 12 |
| death | 3,521 | 0.9 | 0.9 | 23 |
| drug ineffective | 4,903 | 0.8 | 0.8 | 158 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.